Joshua D. Ochocki
Pfizer (United States)(US)
Publications by Year
Research Areas
Cancer, Hypoxia, and Metabolism, Renal cell carcinoma treatment, Click Chemistry and Applications, Endoplasmic Reticulum Stress and Disease, Cancer, Lipids, and Metabolism
Most-Cited Works
- → Fructose-1,6-bisphosphatase opposes renal carcinoma progression(2014)532 cited
- → HIF2α-Dependent Lipid Storage Promotes Endoplasmic Reticulum Homeostasis in Clear-Cell Renal Cell Carcinoma(2015)400 cited
- → Nutrient-sensing pathways and metabolic regulation in stem cells(2013)137 cited
- → Arginase 2 Suppresses Renal Carcinoma Progression via Biosynthetic Cofactor Pyridoxal Phosphate Depletion and Increased Polyamine Toxicity(2018)133 cited
- → Evaluation of Alkyne‐Modified Isoprenoids as Chemical Reporters of Protein Prenylation(2010)86 cited
- → Epigenetic re-expression of HIF-2α suppresses soft tissue sarcoma growth(2016)73 cited
- → Prenyltransferase inhibitors: treating human ailments from cancer to parasitic infections(2012)68 cited
- → Metabolic Labeling with an Alkyne-modified Isoprenoid Analog Facilitates Imaging and Quantification of the Prenylome in Cells(2016)48 cited
- → Prediction and Evaluation of Protein Farnesyltransferase Inhibition by Commercial Drugs(2010)40 cited
- → A combination of metabolic labeling and 2D-DIGE analysis in response to a farnesyltransferase inhibitor facilitates the discovery of new prenylated proteins(2014)34 cited